Projected top future IBD drugs based on expected 2022 revenue

This statistic displays a projection of the top future inflammatory bowel disease drugs based on expected 2022 revenues worldwide. During this time, Janssen's Stelara, a therapy targeting Crohn's disease with expected approval in 2015, is expected to generate 399.5 million U.S. dollars in 2022 revenues. Approximately, 1 to 1.3 million people currently suffer from IBD in the United States, however, the cause of IBD is currently unknown. IBD occurs in the colon and intestine and can also impact other parts of the body.

Top future inflammatory bowel disease drugs by expected 2022 revenue

Loading statistic...
You need to log in to download this statistic
Register for free
Already a member?
Log in
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

August 2014

Region

Worldwide

Survey time period

2014

Supplementary notes

UC: ulcerative colitis; CD: Crohn's disease.
* Only in major 5 EU markets.

Statista Accounts: Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Inflammatory bowel disease (IBD) in the U.S. "

Statista Accounts: Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.